NCT01059617View on ClinicalTrials.gov

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

February 9, 2010

Primary Completion Date

January 14, 2011

Study Completion Date

October 21, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' FluLaval®

Intramuscular injection

BIOLOGICAL

Placebo (saline)

Intramuscular injection

BIOLOGICAL

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A

Intramuscular injections

BIOLOGICAL

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A

Intramuscular injections

Trial Locations (3)

27103

GSK Investigational Site, Winston-Salem

28144

GSK Investigational Site, Salisbury

01757

GSK Investigational Site, Milford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01059617 - Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults | Biotech Hunter | Biotech Hunter